Collplant Biotechnologies Stock Performance
| CLGN Stock | USD 2.45 0.24 10.86% |
On a scale of 0 to 100, Collplant Biotechnologies holds a performance score of 5. The firm shows a Beta (market volatility) of -0.58, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Collplant Biotechnologies are expected to decrease at a much lower rate. During the bear market, Collplant Biotechnologies is likely to outperform the market. Please check Collplant Biotechnologies' total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power , to make a quick decision on whether Collplant Biotechnologies' price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Collplant Biotechnologies are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating technical and fundamental indicators, Collplant Biotechnologies displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 10.86 | Five Day Return 30.32 | Year To Date Return (35.70) | Ten Year Return (72.78) | All Time Return (72.78) |
Last Split Factor 2:3 | Dividend Date 2016-11-21 | Last Split Date 2016-11-21 |
1 | Williams Companies To Rally Over 11 Here Are 10 Top Analyst Forecasts For Wednesday | 05/28/2025 |
2 | CollPlant Biotechnologies Rating and Price Target Analysis CLGN Stock News | 05/30/2025 |
3 | CollPlant Biotechnologies shares slide after announces capital raise of 3.6M through registered direct offering - MSN | 06/02/2025 |
4 | CollPlant Secures European Patent for Injectable Fillers and Implants CLGN Stock News | 06/04/2025 |
5 | CollPlant Biotechnologies Shares Surge on Expanded STEMCELL Partnership | 06/09/2025 |
6 | CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial ... | 07/14/2025 |
7 | What drives CollPlant Biotechnologies Ltd. stock price - High-yield investments - jammulinksnews.com | 07/22/2025 |
| Begin Period Cash Flow | 26.7 M | |
| Total Cashflows From Investing Activities | -539 K |
Collplant | Build AI portfolio with Collplant Stock |
Collplant Biotechnologies Relative Risk vs. Return Landscape
If you would invest 222.00 in Collplant Biotechnologies on April 25, 2025 and sell it today you would earn a total of 23.00 from holding Collplant Biotechnologies or generate 10.36% return on investment over 90 days. Collplant Biotechnologies is currently generating 0.9108% in daily expected returns and assumes 13.4087% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Collplant, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Collplant Biotechnologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Collplant Biotechnologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Collplant Biotechnologies, and traders can use it to determine the average amount a Collplant Biotechnologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0679
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CLGN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.41 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.91 actual daily | 18 82% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Collplant Biotechnologies is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Collplant Biotechnologies by adding it to a well-diversified portfolio.
Collplant Biotechnologies Fundamentals Growth
Collplant Stock prices reflect investors' perceptions of the future prospects and financial health of Collplant Biotechnologies, and Collplant Biotechnologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Collplant Stock performance.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (0.80) % | ||||
| Current Valuation | 23.26 M | ||||
| Shares Outstanding | 12.72 M | ||||
| Price To Earning | 92.60 X | ||||
| Price To Book | 2.51 X | ||||
| Price To Sales | 12.60 X | ||||
| Revenue | 515 K | ||||
| Gross Profit | 1.2 M | ||||
| EBITDA | (16.21 M) | ||||
| Net Income | (16.61 M) | ||||
| Cash And Equivalents | 36.29 M | ||||
| Cash Per Share | 3.27 X | ||||
| Total Debt | 3.08 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 16.21 X | ||||
| Book Value Per Share | 1.08 X | ||||
| Cash Flow From Operations | (14.09 M) | ||||
| Earnings Per Share | (1.21) X | ||||
| Market Capitalization | 31.15 M | ||||
| Total Asset | 18.71 M | ||||
| Retained Earnings | (113.35 M) | ||||
| Working Capital | 10.21 M | ||||
| Current Asset | 17.03 M | ||||
| Current Liabilities | 6.37 M | ||||
About Collplant Biotechnologies Performance
By examining Collplant Biotechnologies' fundamental ratios, stakeholders can obtain critical insights into Collplant Biotechnologies' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Collplant Biotechnologies is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 98.83 | 93.89 | |
| Return On Tangible Assets | (0.89) | (0.94) | |
| Return On Capital Employed | (1.10) | (1.15) | |
| Return On Assets | (0.89) | (0.93) | |
| Return On Equity | (1.23) | (1.30) |
Things to note about Collplant Biotechnologies performance evaluation
Checking the ongoing alerts about Collplant Biotechnologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Collplant Biotechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Collplant Biotechnologies is way too risky over 90 days horizon | |
| Collplant Biotechnologies appears to be risky and price may revert if volatility continues | |
| Collplant Biotechnologies has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 515 K. Net Loss for the year was (16.61 M) with profit before overhead, payroll, taxes, and interest of 1.2 M. | |
| Collplant Biotechnologies currently holds about 36.29 M in cash with (14.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.27, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Collplant Biotechnologies has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: What drives CollPlant Biotechnologies Ltd. stock price - High-yield investments - jammulinksnews.com |
- Analyzing Collplant Biotechnologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Collplant Biotechnologies' stock is overvalued or undervalued compared to its peers.
- Examining Collplant Biotechnologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Collplant Biotechnologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Collplant Biotechnologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Collplant Biotechnologies' stock. These opinions can provide insight into Collplant Biotechnologies' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collplant Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.21) | Revenue Per Share | Quarterly Revenue Growth 19.969 | Return On Assets | Return On Equity |
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.